CTLA4 and neoplasm: In our study, application of IRE prior to anti-CTLA-4 therapy promoted profound changes in the neoantigen-specific T cell response, resulting in increased numbers of SPAS-1+ T cells systemically in the spleen and concentrated in the tumor and distant sites.